Astrazeneca releases trial data on oral weight loss medication, with patients using the drug for four weeks experiencing nearly a 6% weight reduction.
①Astrazeneca reported that its oral small molecule weight loss drug AZD5004/ECC5004 reduced the average weight of patients by 5.8% within four weeks in early studies, and showed good tolerability; ② Astrazeneca acquired the global exclusive rights to the drug from Creentech for 2 billion US dollars last year, which is currently in the clinical research stage.
How to Boost Your Portfolio With Top Medical Stocks Set to Beat Earnings
AstraZeneca (AZN) Gets a Sell From Deutsche Bank
AstraZeneca Says Obesity Pill Well Tolerated by Type-2 Diabetes Patients, Competitive
AstraZeneca's Promising Obesity Treatment Advances Justify Buy Rating: Analyst Report
Express News | Huaren pharmaceutical: Sodium Aescinate injection obtained Pharmaceutical registration certificate.